Overview of Uribeta

Property	Description
Active Ingredient	Interferon Beta-1a
Form	Solution for injection (in pre-filled pen or vial)
Pharmacological Class	Immunomodulator, Biological Response Modifier
General Purpose	Disease-Modifying Therapy (DMT)
Origin	Biotechnology-derived, Recombinant Protein

What Type of Medicine is Uribeta?

Uribeta is a specialized, prescription-only biological medicine classified as an immunomodulator. The medicine’s core component is Interferon Beta-1a, a highly specific protein that serves as a cytokine, which are natural signaling molecules within the immune system.

This medicine is created through biotechnology, where the human gene for interferon is introduced into Chinese Hamster Ovary (CHO) cells to produce the recombinant human interferon Beta-1a. This manufacturing process is essential because, as a complex glycoprotein, the molecule requires the machinery of mammalian cells to ensure its structure closely resembles the natural human interferon protein. This type of recombinant protein is recognized for its targeted immunoregulatory properties and places Uribeta within the class of biological response modifiers, signifying its role is to regulate and balance the body's immune pathways.

Composition, Form, and General Purpose

Uribeta is a single-ingredient product supplied as a sterile aqueous solution for injection, designed for parenteral delivery via subcutaneous injection or intramuscular injection. The formulation involves suspending the Interferon Beta-1a in a sterile, water-based vehicle containing necessary stabilizing agents, often packaged in a pre-filled pen or vial to facilitate administration.

The overarching purpose of Uribeta is to function as a Disease-Modifying Therapy (DMT). Its general therapeutic goal is to exert an immunoregulatory effect by influencing cellular communication and modulating the balance of pro- and anti-inflammatory cytokines. Interferons like this possess inherent anti-inflammatory activity which is key to their mechanism of action. This fundamental anti-inflammatory action is intended to favorably influence the course of conditions driven by immune system dysregulation by limiting the frequency of inflammatory events. The medicine's objective is to modulate the disease's underlying trajectory.

Regulatory References

World Health Organization (WHO)

What side effects are possible with Uribeta?

Possible side effects and safety information

The safety profile for Uribeta (Interferon Beta-1a) is based on classifications detailed in official regulatory prescribing information, grouping potential adverse reactions by frequency and physiological system. This information is derived from documented clinical trials and post-marketing surveillance.

Adverse Reaction Frequencies

Side effects are officially classified based on their observed frequency:

Very Common (affecting ge 1 in 10 patients): The most frequently expected reactions are flu-like symptoms (including fever, headache, and chills) and reactions at the injection site (such as pain, redness, and swelling). Lymphopenia is also classified as a very common reaction.
Common (affecting ge 1 in 100 to < 1 in 10 patients): Reactions include depression, insomnia, diarrhea, and vomiting. Rash and the elevation of liver enzymes (transaminases) are commonly reported safety observations.
Uncommon to Rare: Less frequent reactions include thrombocytopenia (low platelet count), suicide attempt, and rare but severe events such as anaphylaxis and severe hepatic injury (including liver failure).

Key Safety Considerations

Safety notes in the official labeling specify that the incidence of flu-like symptoms and local injection site reactions is typically higher at the start of therapy and often diminishes with continued treatment. Conversely, the risk of developing neutralizing antibodies is associated with long-term exposure.

Regulatory documents highlight the potential for Serious Adverse Reactions, including the risk of severe depression and suicidal ideation and the development of new or worsening cardiac dysfunction (such as congestive heart failure), particularly in patients with pre-existing heart conditions. Formal contraindications exist for individuals with uncontrolled severe depression. Ongoing safety monitoring requires periodic evaluation of complete blood counts and liver function tests throughout the course of treatment, as mandated by regulatory authorities.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented information regarding Uribeta (Interferon Beta-1a) overdose, as specified in government regulatory documents.

Suspected overdose, often associated with the accidental administration of multiple weekly doses, requires immediate medical attention. Individuals should contact a poison control center or emergency room without delay. The patient should take the product package and any remaining medication to the healthcare provider.

Documented Overdose Manifestations

The most consistent physiological sign of overdose documented in prescribing information is a significant elevation of hepatic enzymes (ALT and AST). While acute systemic symptoms are generally rare, the major severe risk cited is hepatic injury or hepatotoxicity.

Management and Monitoring Requirements

Official regulatory sources confirm that no specific antidote is known for Interferon Beta-1a overdose. Consequently, the required treatment strategy is limited to symptomatic and supportive treatment to manage clinical signs that may arise.

Close clinical and laboratory monitoring is mandated, including frequent testing of liver enzyme levels and Complete Blood Count (CBC). Hospital monitoring may be required until laboratory markers stabilize following the excessive exposure.

Therapeutic Uses of Uribeta

What Uribeta Treats: Main Uses and Benefits

Uribeta (Interferon Beta-1a) is a medication generally used for the long-term management of Relapsing Forms of Multiple Sclerosis (MS). Its therapeutic focus is on conditions involving inflammatory or irritative processes that affect functional stability. It is applied across domains where additional symptomatic support may be appropriate. The information is aligned with the official indications for the medication.

The medication is considered relevant in conditions involving Relapsing-Remitting MS (RRMS), Active Secondary Progressive MS (SPMS), and following a first episode known as Clinically Isolated Syndrome (CIS). The primary therapeutic goal is to help reduce the frequency of clinical exacerbations—the unpredictable episodes characterized by symptoms of increased neurological activity, such as weakness, numbness, or coordination problems.

“The therapeutic objective is to contribute to slowing the accumulation of physical disability over time.”

This approach helps patients cope more steadily with symptom fluctuations. It supports patients during difficult episodes by easing distress and may assist with maintaining functional stability and preserving mobility and independence over time.

Quick Fact: Support for Episodic Symptoms
Common Use: Used in situations involving recurrent or episodic manifestations.
Main Benefit: Provides support that helps ease the overall symptom burden during periods of heightened symptoms.
Symptom Focus: Helps address symptom clusters that become more disruptive during flare-ups, such as motor and sensory dysfunction.

Eligibility and Restrictions for Use

Who Can and Cannot Use Uribeta?

The population eligibility for Uribeta (Interferon Beta-1a) is strictly defined by official regulatory labeling, outlining specific groups for whom the medicine is approved, restricted, or prohibited.

Contraindications (Absolute Non-Eligibility)

Uribeta is contraindicated and must not be used by individuals with a history of hypersensitivity to natural or recombinant interferon beta or to any other component of the formulation. Patients with current severe depression or suicidal ideation are also considered contraindicated in some regulatory documents.

Age and Disease Eligibility

The medicine is approved for use in adults with Relapsing Forms of Multiple Sclerosis (MS). While some specific formulations are authorized for children aged 2 years and older, use in older adults (65 and over) is often supported by insufficient clinical data.

Restricted Use Group	Regulatory Status
Severe Organ Impairment (Hepatic/Renal)	Use requires caution and close monitoring.
Significant Cardiac Disease	Use requires caution and close monitoring.
Pregnancy/Lactation	Conditional use; generally permitted but requires clinical judgment.

Eligibility is not established for patients with Primary Progressive Multiple Sclerosis (PPMS).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents indicate that no formal human-specific interaction studies have been conducted for Uribeta (Interferon Beta-1a). The documented interaction profile is based on reported pharmacological effects and potential additive risks, presented at a high-level regulatory basis.

Pharmacokinetic and Metabolic Interactions

Interferon-based medicines are officially reported to have the potential to reduce the activity of hepatic cytochrome P450-dependent enzymes (CYP). This pharmacokinetic effect leads to a specific regulatory caution for co-administration with medicinal products that have a narrow therapeutic index and whose clearance is largely dependent on the CYP system. Products explicitly cited in this category include certain antiepileptics and antidepressants, due to the potential risk of increased plasma exposure or accumulation of the co-administered drug.

Pharmacodynamic and Substance Interactions

There is a documented risk of additive hepatic injury when Uribeta is co-administered with other hepatotoxic drugs. This additive risk also applies to substances such as alcohol (Ethanol), and caution regarding combination with these agents must be considered. Furthermore, regulatory labels note that no specific foods must be excluded from the diet during treatment. While no timing-based interaction rules are required for risk mitigation, the concurrent use of analgesics or antipyretics is noted as a strategy to help manage transient flu-like symptoms.

Mechanism of Action

How Uribeta Works

Receptor Activation and Intracellular Signaling

The action of Interferon Beta-1a begins at the cell surface, where it acts as an agonist for the Type I Interferon Receptor (IFNAR). This specific binding event rapidly initiates the JAK-STAT signaling cascade, a mechanism that ultimately modulates the transcription of hundreds of Interferon-Stimulated Genes (ISGs) in the cell nucleus. This domain drives the initial genetic reprogramming that leads to all downstream physiological effects.

Modulating Immune Cell Balance and Output

The altered gene expression fundamentally shifts the immune system's profile. The mechanism regulates the activity and proliferation of pro-inflammatory immune cells (like Th1 and Th17 cells) while simultaneously promoting the output of key anti-inflammatory mediators such as Interleukin-10 (IL-10). This systemic modulation influences the balance of physiological responses and promotes a regulated immune state.

Restricting Inflammatory Cell Trafficking

A key consequence of the mechanism is the regulation of cell movement. The drug's action limits the expression of specific adhesion molecules (such as VLA-4) on the surface of circulating leukocytes. By restricting the ability of these inflammatory cells to adhere to and cross the Blood-Brain Barrier (BBB), the mechanism limits the infiltration and accumulation of immune cells within central nervous system tissues.

Dosage and Administration Information

Administration Method

Uribeta is typically administered orally. The medication is designed to be swallowed whole with a sufficient amount of liquid, such as a glass of water. It can generally be taken with or without food, depending on individual tolerance and specific medical advice.

Consistency in Use

For the medication to maintain its effectiveness, it is important to take it at the same time each day. This helps maintain a steady level of the active substance in the body. If a dose is missed, individuals should consult the provided patient information leaflet regarding the appropriate steps to take, rather than doubling the next dose.

Duration of Use

The duration of treatment is determined by a healthcare professional based on the underlying condition being addressed. It is common for the effects of the medication to be observed over a period of several weeks. Monitoring by a healthcare provider is standard practice to evaluate the ongoing necessity and response to the medication.

Handling and Storage

The medication should be kept in its original packaging to protect it from environmental factors such as moisture and light. It should be stored at room temperature and kept out of the reach of children.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uribeta

Evidence for Use in Relapsing-Remitting Multiple Sclerosis (RRMS)

Research exploring Uribeta (Interferon Beta-1a) in adults with Relapsing-Remitting Multiple Sclerosis (RRMS) primarily involves several large, short-term Randomized, Controlled Trials (RCTs). These studies compared patient outcomes when receiving the medicine against those receiving a placebo (an inactive substance) over observation periods typically lasting two to four years. The main outcomes monitored were measures of clinical disease activity, such as the annualized frequency of relapses, and the progression of long-term physical disability assessed using standardized functional scales.

In the studies, researchers reported measurements of lower relapse rates in the groups receiving the medicine compared to the placebo groups over the study period. Additionally, patterns were described where the time to a sustained worsening of physical disability was observed to be longer in the groups receiving the medicine. The research also examined radiological outcomes using MRI, and the findings described patterns of fewer new or active lesions in the brain compared to the control groups. This type of research contributes to the broader evidence landscape for understanding clinical and radiological activity patterns in RRMS.

Evidence for Treatment Following a First Event (Clinically Isolated Syndrome, CIS)

Uribeta was studied for its use in individuals who have experienced a first, isolated neurological episode suggestive of MS, a condition known as Clinically Isolated Syndrome (CIS). These specialized RCTs explored whether initiating the medicine after the first event could affect the subsequent classification of MS.

Findings from these studies suggest that patients who received the medicine early had a longer time to conversion to Clinically Definite Multiple Sclerosis (CDMS) compared to those who received a delayed or placebo treatment. The trials also monitored the accumulation of new lesions on MRI scans. What remains uncertain is the long-term implication of this initial approach on final disability accumulation decades later, as the original study durations were primarily focused on the time to the second event.

Long-Term Studies and Evidence Gaps

Researchers have conducted extensive open-label follow-up studies to monitor patients from the initial RCTs over many years, often extending up to 8 to 15 years. These studies were evaluated in an observational setting to provide context for long-term patient experiences. These findings describe patterns observed related to disability outcomes and clinical activity levels in many patients who were monitored in the long-term. However, because patients were no longer randomized, causal inferences between long-term usage and final outcomes are not fully established, and the evidence quality varies across these extension studies.

Despite the research base, data for certain groups remain insufficient for high-certainty conclusions. For example, direct head-to-head research comparing Uribeta against all of the newer types of therapies for MS is limited. Additionally, data for Secondary Progressive MS (SPMS) patients who have little to no ongoing relapse activity remain limited, making it uncertain how this medicine may influence the purely progressive phase of the condition.

Frequently Asked Questions (FAQ)

Common questions about Uribeta (FAQ)

Q: Can Uribeta be used for bladder control issues not related to infection?

A: Uribeta (Interferon Beta-1a) is officially indicated for the treatment of relapsing forms of multiple sclerosis (MS). Regulatory documents do not list bladder control issues not related to MS as an approved use for this medicine.

Q: Is Uribeta generally considered a short-term or long-term medication?

A: This medicine is designated as a Disease-Modifying Therapy (DMT) for multiple sclerosis, which is a chronic condition. Regulatory documents indicate its classification and use protocols are consistent with continuous, long-term administration. Treatment is structured around an initial dose adjustment period followed by a consistent, long-term maintenance schedule.

Q: Can Uribeta interact with diabetes medications?

A: Regulatory documents include a general caution that Uribeta may reduce the activity of certain liver enzymes, known as the Cytochrome P450 (CYP) system. This effect raises a caution for its use alongside other medicines, including some that treat diabetes, that are highly dependent on this system for clearance. Official regulatory materials indicate that monitoring is advised by healthcare professionals when co-administering such medicines.

Q: Has Uribeta been studied in pregnant people?

A: Studies on the use of interferon beta products during early pregnancy have been collected and analyzed. Official information from these studies indicates that there was no increased risk of major birth defects observed, but the label does not conclude absolute safety.

Q: Can I drive or operate machinery while taking Uribeta?

A: The official label notes that caution should be exercised regarding driving or operating machinery. Adverse reactions, such as dizziness or fainting (syncope), may occur with the medicine, and these effects could potentially influence a person’s ability to perform these tasks safely.

Q: Can Uribeta cause headaches?

A: Yes, official safety information lists headache as a very common adverse reaction, meaning it has been reported in more than 1 in 10 patients. Headaches are often reported as part of the flu-like symptoms that are more frequently experienced when treatment is first started.

Q: Do I need a prescription to get Uribeta?

A: Uribeta is a specialized medicine and is classified as a prescription-only (Rx-only) drug. This legal status is mandated by regulatory agencies in the U.S. and other international health authorities.

Q: How quickly is Uribeta expected to start working?

A: Clinical trial summaries focus on the medicine's long-term effectiveness in influencing the course of multiple sclerosis. For example, one trial found the median time to a patient's first relapse was longer for those receiving the medicine (approximately 7.6 to 9.6 months) compared to those receiving placebo (4.5 months) during the first two years of the study.

Q: How long can a person typically stay on Uribeta?

A: The medicine is approved for long-term use as a treatment for chronic multiple sclerosis. The evidence base includes long-term follow-up studies that have monitored patients for periods extending up to 8 to 15 years.

Q: Can Uribeta make me feel unusually tired?

A: Yes, official product information indicates that tiredness (also described as asthenia or fatigue) is a reported side effect of the medicine. It is a common symptom often reported as part of the flu-like symptoms that may occur, especially during the initial phase of treatment.

Q: Does Uribeta interact with caffeine?

A: Information derived from pharmacological studies suggests that Uribeta may decrease the rate at which the body metabolizes caffeine. This indicates that the metabolism of caffeine may be slower in the presence of the medicine.

Q: What is the difference between Uribeta and an antispasmodic drug?

A: Uribeta (Interferon Beta-1a) is officially classified as an immunomodulator and a biological response modifier, as its active component is a protein that regulates the immune system. This makes it distinct from antispasmodic drugs, which belong to a different class of medicines that primarily function to relax muscles and reduce spasms.

Q: Are there specific symptoms that mean Uribeta is not working for me?

A: The medicine is intended to reduce the frequency of clinical exacerbations (relapses) and slow the progression of physical disability. Persistent or increasing disease activity, such as relapses or progression of disability, are the measures used in clinical trials to assess response to the medicine.

Q: Is it okay to drink alcohol while using Uribeta?

A: Official safety documents note a potential risk of additive hepatic injury when this medicine is used alongside other substances that are known to be harmful to the liver, including alcohol (Ethanol). Official information indicates that monitoring for signs of liver injury may be necessary during treatment.

Q: What happens if a child accidentally takes Uribeta?

A: Official labeling contains a clear safety warning to Keep out of the reach of children. While the medicine is approved for use in certain children (aged 2 years and older for some types), the label instructs on proper storage to prevent accidental exposure, but does not provide specific overdose instructions.

Q: Does Uribeta require any special monitoring or regular blood tests?

A: Yes, official regulatory safety guidelines mandate the periodic evaluation and monitoring of specific laboratory tests throughout the course of treatment. The official requirements include periodic evaluation of complete blood counts and liver function tests (transaminases).

Q: Are there specific age limits for who can use Uribeta?

A: The medicine is approved for use in adults with relapsing MS. Official information states that some formulations are authorized for use in children aged 2 years and older. However, use in older adults (65 and over) is noted as being supported by insufficient clinical data.

Q: How is Uribeta typically eliminated from the body?

A: The medicine’s active component, Interferon beta-1a, is a protein that is mainly processed and cleared from the body by the liver and the kidneys. This is the pathway described in the official pharmacokinetic information.

Q: Does Uribeta affect blood pressure readings?

A: The official label notes the potential for new or worsening cardiac dysfunction, such as congestive heart failure, particularly in patients with pre-existing heart conditions. Reports of low blood pressure and abnormal heartbeat have also been noted in postmarketing surveillance.

Q: Are there any special instructions for storing Uribeta at home?

A: Yes, Uribeta requires strict storage conditions as a refrigerated product. It must be stored under refrigerated conditions (between 2 C to 8 C), kept in its original carton to protect it from light. The regulatory label indicates the medicine should not be frozen.

Q: Can Uribeta be crushed or chewed if I have trouble swallowing pills?

A: Uribeta is not an oral tablet or pill. The medicine is supplied as a sterile solution for injection in specialized devices like a pre-filled pen, and it must be administered only via either subcutaneous or intramuscular injection.

How should Uribeta be stored and disposed of?

How to Store and Dispose of Interferon Beta-1a

Storage and disposal requirements for this medicine, a biological injectable, are mandated by regulatory agencies to maintain its stability. The product must be stored under refrigerated conditions between 2°C to 8°C (36°F to 46°F).

Storage Restriction	Requirement
Freezing	Do not freeze the solution.
Light	Keep the medicine in its original carton to protect it from light.
Child Safety	Keep out of the reach of children.

The official labeling defines maximum room temperature exposure limits, which allow temporary storage up to 25°C (77°F) for a specific, limited duration. All used needles, syringes, and autoinjectors must be disposed of immediately in an FDA-cleared, puncture-resistant sharps container. These materials must not be reused or thrown into household trash.

Uribeta